Shares of AlloVir, Inc. (ALVR) have gained 2.7% over the past four weeks to close the last trading session at $6.03, but there could still be a solid upside left in the stock if short-term price ...
AlloVir, Inc. (ALVR) closed the last trading session at $7.83, gaining 45.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...
As of April 24, 2023, the average one-year price target for AlloVir is 22.44. The forecasts range from a low of 16.16 to a high of $31.50. The average price target represents an increase of 544.83% ...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AlloVir, Inc. (NASDAQ: ALVR) and Kalaris Therapeutics is fair to AlloVir shareholders.
Apple Vision Pro, a headset-type spatial computing device, is equipped with the M2 chip and R1 chip, and allows you to experience high-quality VR (virtual space) and AR (augmented reality) by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results